Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real-Life Campus CLL Study
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real-Life Campus CLL Study
Rigolin, Gian Matteo;Cuneo, AntonioPenultimo
;
2022
Abstract
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real-Life Campus CLL StudyFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
American J Hematol - 2021 - Visentin - Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted.pdf
accesso aperto
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
1.94 MB
Formato
Adobe PDF
|
1.94 MB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
